Does the media refer more to FBIO or CLRB?

In the previous week, Fortress Biotech had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Fortress Biotech and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.93 beat Fortress Biotech's score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRCA or CLRB?

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ICCC or CLRB?

Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 376.19%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Does the media refer more to ICCC or CLRB?

In the previous week, ImmuCell and ImmuCell both had 2 articles in the media. ImmuCell's average media sentiment score of 1.52 beat Cellectar Biosciences' score of 0.93 indicating that ImmuCell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MNOV or CLRB?

In the previous week, MediciNova and MediciNova both had 2 articles in the media. MediciNova's average media sentiment score of 0.93 equaled Cellectar Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CLRB or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A Alterity Therapeutics N/A N/A -$15.88M N/A N/A

Is CLRB or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -185.35% -115.42% Alterity Therapeutics N/A N/A N/A

Does the media favor CLRB or ATHE?

In the previous week, Alterity Therapeutics had 3 more articles in the media than Cellectar Biosciences. MarketBeat recorded 5 mentions for Alterity Therapeutics and 2 mentions for Cellectar Biosciences. Alterity Therapeutics' average media sentiment score of 1.22 beat Cellectar Biosciences' score of 0.93 indicating that Alterity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Cellectar Biosciences (CLRB) Competitors

$2.31 -0.06 (-2.53%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.32 +0.01 (+0.43%)

As of 09/11/2026 07:50 PM Eastern

Compare

CLRB vs. FBIO, VRCA, ICCC, MNOV, and ATHE

Should you buy Cellectar Biosciences stock or one of its competitors? Cellectar Biosciences's main competitors and comparable companies include Fortress Biotech (FBIO), Verrica Pharmaceuticals (VRCA), ImmuCell (ICCC), MediciNova (MNOV), and Alterity Therapeutics (ATHE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cellectar Biosciences compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, Fortress Biotech had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Fortress Biotech and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.93 beat Fortress Biotech's score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.33	$6.82M	$2.64	0.95
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

Fortress Biotech presently has a consensus target price of $17.00, indicating a potential upside of 574.60%. Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 376.19%. Given Fortress Biotech's higher probable upside, equities analysts clearly believe Fortress Biotech is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Fortress Biotech has a net margin of 163.32% compared to Cellectar Biosciences' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Cellectar Biosciences	N/A	-185.35%	-115.42%

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Fortress Biotech has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

Summary

Fortress Biotech beats Cellectar Biosciences on 12 of the 16 factors compared between the two stocks.

How does Cellectar Biosciences compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Verrica Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Verrica Pharmaceuticals currently has a consensus price target of $12.67, suggesting a potential upside of 157.98%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 376.19%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Cellectar Biosciences has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Cellectar Biosciences' return on equity of -185.35% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Cellectar Biosciences	N/A	-185.35%	-115.42%

Verrica Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.37	-$17.89M	-$1.67	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Verrica Pharmaceuticals beats Cellectar Biosciences on 8 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

ImmuCell has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.24	-$1.04M	$0.08	123.13
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

ImmuCell has a net margin of 2.57% compared to Cellectar Biosciences' net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Cellectar Biosciences	N/A	-185.35%	-115.42%

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 376.19%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, ImmuCell and ImmuCell both had 2 articles in the media. ImmuCell's average media sentiment score of 1.52 beat Cellectar Biosciences' score of 0.93 indicating that ImmuCell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuCell has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Summary

ImmuCell beats Cellectar Biosciences on 9 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

MediciNova has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

In the previous week, MediciNova and MediciNova both had 2 articles in the media. MediciNova's average media sentiment score of 0.93 equaled Cellectar Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MediciNova presently has a consensus price target of $8.33, suggesting a potential upside of 360.41%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 376.19%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Cellectar Biosciences has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Cellectar Biosciences	N/A	-185.35%	-115.42%

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MediciNova has higher revenue and earnings than Cellectar Biosciences. MediciNova is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	217.29	-$12M	-$0.21	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

Summary

MediciNova beats Cellectar Biosciences on 7 of the 12 factors compared between the two stocks.

How does Cellectar Biosciences compare to Alterity Therapeutics?

Cellectar Biosciences (NASDAQ:CLRB) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Alterity Therapeutics' return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-185.35%	-115.42%
Alterity Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cellectar Biosciences presently has a consensus price target of $11.00, suggesting a potential upside of 376.19%. Alterity Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 146.91%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cellectar Biosciences is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Alterity Therapeutics had 3 more articles in the media than Cellectar Biosciences. MarketBeat recorded 5 mentions for Alterity Therapeutics and 2 mentions for Cellectar Biosciences. Alterity Therapeutics' average media sentiment score of 1.22 beat Cellectar Biosciences' score of 0.93 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alterity Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Summary

Alterity Therapeutics beats Cellectar Biosciences on 7 of the 12 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLRB vs. The Competition

Export

Metric	Cellectar Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.83M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-0.60	799.75	274.94	25.33
Price / Sales	N/A	756.96	633.80	90.72
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	1.22	10.39	10.33	6.21
Net Income	-$21.79M	$2.85B	$3.50B	$358.54M
7 Day Performance	-2.53%	-3.61%	-3.32%	-2.35%
1 Month Performance	-5.71%	0.72%	-0.53%	-3.23%
1 Year Performance	-54.53%	3.61%	23.51%	8.79%

Cellectar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLRB Cellectar Biosciences	2.3394 of 5 stars	$2.31 -2.5%	$11.00 +376.2%	-54.5%	$21.83M	N/A	N/A	10
FBIO Fortress Biotech	2.2354 of 5 stars	$2.71 -0.4%	$17.00 +527.3%	-35.2%	$90.38M	$63.26M	1.03	170
VRCA Verrica Pharmaceuticals	4.467 of 5 stars	$5.26 -0.8%	$12.67 +140.8%	+3.4%	$90.37M	$35.58M	N/A	40
ICCC ImmuCell	1.4997 of 5 stars	$9.84 -0.6%	N/A	+66.4%	$89.35M	$27.64M	123.02	70
MNOV MediciNova	1.8706 of 5 stars	$1.75 +7.4%	$8.33 +376.2%	+47.2%	$86.14M	$410K	N/A	10	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLRB) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectar Biosciences (CLRB) Competitors

CLRB vs. FBIO, VRCA, ICCC, MNOV, and ATHE

How does Cellectar Biosciences compare to Fortress Biotech?

Summary

How does Cellectar Biosciences compare to Verrica Pharmaceuticals?

Summary

How does Cellectar Biosciences compare to ImmuCell?

Summary

How does Cellectar Biosciences compare to MediciNova?

Summary

How does Cellectar Biosciences compare to Alterity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectar Biosciences (CLRB) Competitors

CLRB vs. FBIO, VRCA, ICCC, MNOV, and ATHE

How does Cellectar Biosciences compare to Fortress Biotech?

Does the media refer more to FBIO or CLRB?

Which has higher earnings & valuation, FBIO or CLRB?

Do analysts rate FBIO or CLRB?

Is FBIO or CLRB more profitable?

Do institutionals & insiders believe in FBIO or CLRB?

Which has more risk and volatility, FBIO or CLRB?

Summary

How does Cellectar Biosciences compare to Verrica Pharmaceuticals?

Which has more volatility & risk, VRCA or CLRB?

Do analysts rate VRCA or CLRB?

Is VRCA or CLRB more profitable?

Which has higher earnings and valuation, VRCA or CLRB?

Do institutionals & insiders believe in VRCA or CLRB?

Does the media favor VRCA or CLRB?

Summary

How does Cellectar Biosciences compare to ImmuCell?

Which has stronger valuation & earnings, ICCC or CLRB?

Is ICCC or CLRB more profitable?

Do insiders & institutionals believe in ICCC or CLRB?

Do analysts prefer ICCC or CLRB?

Does the media refer more to ICCC or CLRB?

Which has more risk & volatility, ICCC or CLRB?

Summary

How does Cellectar Biosciences compare to MediciNova?

Which has more risk and volatility, MNOV or CLRB?

Does the media favor MNOV or CLRB?

Do analysts prefer MNOV or CLRB?

Is MNOV or CLRB more profitable?

Do insiders and institutionals hold more shares of MNOV or CLRB?

Which has preferable earnings and valuation, MNOV or CLRB?

Summary

How does Cellectar Biosciences compare to Alterity Therapeutics?

Is CLRB or ATHE more profitable?

Which has better valuation & earnings, CLRB or ATHE?

Do insiders and institutionals hold more shares of CLRB or ATHE?

Do analysts recommend CLRB or ATHE?

Does the media favor CLRB or ATHE?

Which has more volatility and risk, CLRB or ATHE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools